Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-hemolysin is a pore-forming toxin produced by the bacterium *Staphylococcus aureus*. It is synthesized as a 293-residue, water-soluble monomer that binds to susceptible cell membranes, where seven monomers assemble into a heptameric beta-barrel pore. This pore formation disrupts cellular membrane integrity, causing leakage of ions and metabolites, resulting in cell death via either apoptosis or necrosis depending on concentration. Alpha-hemolysin plays a central role in the pathogenesis of S. aureus infections by lysing host cells (including erythrocytes and immune cells), contributing to tissue destruction, immune evasion, and disease severity. It is also widely used as a biotechnological nanopore tool in single-molecule sequencing research[1][2][4][5][7][8].
Binding to host cell membranes (specific receptor not fully identified) Oligomerization (usually as a heptamer) to form a transmembrane beta-barrel pore Pore formation results in uncontrolled ion flux, cell lysis, apoptosis (at low concentrations), and necrosis (at high concentrations)[1][2][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-hemolysin (Hla).